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There has been considerable interest recently in what is known as ‘fragment-
based lead discovery’. The novel feature of the approach is to begin with small
low-afﬁnity compounds. The main advantage is that a larger potential chemical
diversity can be sampled with fewer compounds, which is particularly important
for new target classes. The approach relies on careful design of the fragment
library, a method that can detect binding of the fragment to the protein target,
determination of the structure of the fragment bound to the target, and the
conventional use of structural information to guide compound optimization. In
this article the methods are reviewed, and experiences in fragment-based
discovery of lead series of compounds against kinases such as PDK1 and
ATPases such as Hsp90 are discussed. The examples illustrate some of the key
beneﬁts and issues of the approach and also provide anecdotal examples of the
patterns seen in selectivity and the binding mode of fragments across different
protein targets.
1. Introduction
There has been considerable interest recently in what is known as
‘fragment-based lead discovery’ (Erlanson et al., 2004; Rees et al.,
2004; Hajduk & Greer, 2007), and a number of drugs entering clinical
trials have been discovered using these techniques (Card et al., 2005;
Gill et al., 2005; Petros et al., 2006). The major new advance is to begin
with much smaller (molecular weight Mr < 250) compounds. This has
signiﬁcant advantages in being able to sample a large potential
chemical diversity with a small number of compounds. In most other
respects the methods are similar to the more traditional use of
protein-ligand structures to understand structure–activity relation-
ships (SAR) and to guide optimization of the binding afﬁnity,
selectivity and drug-like characteristics of a compound for a parti-
cular protein active site.
The ideas of fragment-based discovery developed during the 1990s.
Scientists at Abbott pioneered the approach for drug discovery, using
NMR to identify fragments binding in the SAR by the NMR
approach (Shuker et al., 1996). Although various academic groups
had explored systematic binding of solvent molecules to proteins
(Mattos & Ringe, 2001; English et al., 2001), the ﬁrst screening of
fragments by crystallography linked to drug discovery was from
another Abbott group (Nienaber et al., 2000). These ideas were
subsequently developed by various small technology companies
(Rees et al., 2004; Card et al., 2005; Blaney et al., 2006) for more
focused application in drug discovery.
Most approaches to fragment-based discovery rely on careful
design of the fragment library, amethod that can detect the binding of
the fragment to the protein target, determination of the structure of
the fragment bound to the target, and the conventional use of
structural information to guide compound optimization. At Vernalis,
we have developed an approach that we call SeeDs (structural
exploitation of experimental drug startpoints) (Hubbard, Davis et al.,
2007).
2. The SeeDs approach
The essential steps are summarized in Fig. 1 and consist of selecting
a library of suitable fragments, identifying which fragments bind to
the target binding site using NMR or surface plasmon resonance
methods, determination of the structure of the fragments binding to
the protein by X-ray crystallography, and then using the structural
information to guide the evolution of improved hit or lead
compounds.
2.1. Fragment library design
The design of the fragment library is one of the most critical stages,
as in any screening process. Unfortunately, little detail is published
about library design. The limited non-proprietary information that is
available has been summarized recently (Hubbard, Chen & Davis,
2007). Most strategies for the design of fragment libraries include
selection on the presence or absence of either desirable or undesir-
able chemical functionality and this can often be inﬂuenced by the
subsequent chemistry to be used to evolve fragments. In addition, the
methods used to identify which fragments are binding can place
additional constraints on the library in terms of solubility, shape,
ﬂexibility or spectral properties. As an example, Fig.2 summarizes the
cheminformatics workﬂow used to generate an incremental addition
to the Vernalis fragment libraries (Baurin, Aboul-Ela et al., 2004).
The ﬁrst two stages can be performed computationally. The major
investment comes in visual inspection of the compounds to establish
chemical tractability and the extent of physico-chemical quality
control required to generate a ﬁnal library.
2.2. Identifying fragments that bind
Fragments bind extremely weakly to a target with useful fragments
of Mr < 250 binding with afﬁnities ranging from 10 mM to 10 mM.
Measuring such weak binding is a real challenge for most activity andbinding assays because of interference by the high concentrations of
ligand required. For this reason, biophysical methods have proved
popular for identifying binding. Some groups screen using X-ray
crystallography (Rees et al., 2004; Blaney et al., 2006), where mixtures
of fragments are soaked into crystals of the unliganded protein and
difference electron density maps interpreted to identify which frag-
ments have bound. This method immediately provides details of the
structure of the fragment bound to the protein. NMR spectroscopy is
able to monitor binding at this type of concentration with the added
advantage that experiments can readily be conﬁgured to check for
precipitation, protein unfolding, competitive binding and even
mapping where the fragment binds on the protein surface. More
recently, there have been developments in surface plasmon resonance
(such as the Biacore technology) as a complementary or conﬁrmatory
technique which can also directly provide binding afﬁnity data. Each
of these methods has beneﬁts and disadvantages (see review by
Hubbard, Chen & Davis, 2007).
3. Examples of fragments binding to Hsp90 and PDK1
The project teams at Vernalis have used the SeeDs approach to
identify potent selective inhibitors for a number of different proteins,
including various kinases, ATPases and protein–protein interaction
targets. Here, we provide brief information on two recent projects,
Hsp90 and PDK1.
3.1. Hsp90
Hsp90 is a molecular chaperone that stabilizes the ﬁnal stages of
folding of a wide range of proteins in cells under stress. The protein is
important for the survival and growth of cancer cells, where client
proteins include a number of signalling proteins required for cell
growth as well as stabilization of mutated proteins. Hsp90 consists
of three domains, with an N terminal domain harbouring ATPase
activity crucial for turnover ofproteins. Anumber of natural products
and, more recently, synthetic inhibitors have been identiﬁed which
selectively inhibit this ATPase activity, some of which are entering
clinical trials for various cancers (see review by Drysdale et al., 2006).
Vernalis scientists have identiﬁed various series of Hsp90 inhibitors,
including some derived using fragment-based methods.
A fragment library of 790 fragments was assessed for competitive
binding to the Hsp90 binding site. Some 17 fragments were identiﬁed,
one of which (compound 1 in Fig. 3) is a resorcinol. The resorcinol
substructure was used to search a catalogue of commercially available
compounds (Baurin, Richardson et al., 2004). Following assessment
with focused docking (rDock, http://www.ysbl.york.ac.uk/rDock), a
number of compounds were purchased and assayed. From this,
compound 2 was discovered which has an IC50 of less than 0.5 mM.
This is the same compound as identiﬁed by a collaborator in a
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Figure 2
The Vernalis SeeDs process is an example of the steps in fragment-based drug
discovery. See text for explanation.
Figure 3
SAR by catalog: the structure of resorcinol fragment 1 bound to the active site of
Hsp90 was used to select compound 2, which formed the initial lead series that
generated a pre-clinical candidate.
Figure 1
Constructing a fragment library: an example of the pipeline of cheminformatics
calculations used to identify suitable compounds to include in a fragment library.
Figure 4
Fragment evolution: combining structural information about the binding of series
of compounds from the literature and fragment screening to generate the potent
lead compound 9 for the kinase PDK1.medium-throughput screen (Cheung et al., 2005) which has subse-
quently been optimized (Sharp et al., 2007) and is in pre-clinical
development. This is an example of how fragment screening, followed
by ‘SAR by catalogue’ can rapidly identify good lead compounds.
3.2. PDK1
PDK1 is a classical Ser-Thr kinase (Mora et al., 2004). Growth
factors stimulate PI3 kinase to modulate the phosphorylation status
of phospho-inositol lipids. These recruit PDK1 to the membrane via
its PH domain where it can regulate the activity of a closely related
kinase, Akt, by phosphorylation at position T308. Akt modulates the
activity of both growth and metabolic pathways through phosphor-
ylation of GSK3-b. In addition, PDK1 is implicated in the activation
of more than 20 other kinases. PDK1 is over-expressed in some
cancers and recent evidence has emerged that PDK1 is important for
tumour growth (Collins et al., 2005).
Fig. 4 summarizes how information derived from fragments and
literature compounds was combined to derive compound 9, a potent
PDK1 inhibitor. The structure of compound 3 [a known Chk1 inhi-
bitor (Kania et al., 2001)] bound to Chk1 suggested compound 4,
which binds to PDK1 with an IC50 of 3 mM. Compounds 5 and 6 were
two out of the 80 or so fragments identiﬁed by the SeeDs process that
bind to PDK1. Compound 7 is a CDK2 inhibitor which also has
PDK1 activity (Davies et al., 2002). The structure of 7 bound to PDK1
showed that the cyclohexyl ring lies on an essentially hydrophobic
surface in PDK1. The database of available compounds (Baurin,
Aboul-Ela et al., 2004) was searched for compounds that contained
the 5-carboxy pyrazole core of compound 7 and a hydrophobic ring
and which docked successfully into the PDK1 structure (rDock). One
of the subsequent hits was optimized to give compound 8 which
has an IC50 of 1 mM for PDK1. The crystal structures of compounds 4,
5 and 8 bound to PDK1 were determined and suggested compound 9
which is the combination of the benzimidazole from 4 with the core
pyrazole of 5 with the addition of the piperidine from 8. Compound 9
binds with an IC50 of 90 nM. Subsequent optimization has given
higher-afﬁnity compounds, some of which are tolerated in vivo and
show signs of appropriate pharmacodynamic marker effects in
xenograft models.
4. Challenges for fragments
Fragment methods are now ﬁrmly established as a useful approach to
discovering novel hit compounds for some classes of target. It should
be stressed that fragments are intrinsically no different from any
other hit compound; they are just small and weak binders. The main
issues are therefore as follows.
(i) Design of the library of fragments. Most fragment libraries to
date have evolved from analysis of known drug compounds and/or
selection from the commercially available compounds using appro-
priate diversity and physico-chemical properties (reviewed by
Hubbard, Chen & Davis, 2007). There is scope for further design and
synthesis of novel fragments; for example, by considering the three-
dimensional shape and distribution of functionality.
(ii) Detecting such weak binding compounds. There is real scope
for improving the methods for detecting which fragments are binding
to a particular target. Ideally, assays should be available which can
accurately determine binding afﬁnities at up to 10 mM. The current
biophysical methods (SPR and NMR) can provide such information,
but signiﬁcant improvements are required to improve sensitivity,
reduce the tendency for artefacts and the quantity of protein material
required for screening.
(iii) Generating sufﬁcient information with which to grow the
fragments to more potent compounds. As with any compound opti-
mization, the key requirement is generation of sufﬁcient under-
standing of structure–activity relationships for the design of
compound improvements. If the assay (see above) is accurate and
reliable enough, then in principle it should be possible to grow
fragments in the absence of direct structural information. Alter-
natively, if the active site of the protein does not change on binding of
fragments, then itis possible to predict the binding mode of fragments
with some conﬁdence using docking methods. However, currently for
most targets, a crystal structure of the fragment bound to the target is
required to successfully evolve the fragments into hit compounds on
the scale of the assay.
In conclusion, the early pioneers of fragment methods have used
structure-based methods to demonstrate the proof of concept that
weak millimolar-binding small compounds can be evolved into high-
afﬁnity drug-like molecules, and a number of compounds discovered
using these methods are either in or moving towards clinical trials.
These successes have stimulated many companies to develop frag-
ment-based screening strategies and the methods are now ﬁrmly
established as a successful strategy for hit discovery.
Many scientists at Vernalis have contributed to the work
summarized in this article. In particular, Ben Davis has led the
development of the SeeDs approach, Nicolas Baurin and Ijen Chen
have developed the informatics and modelling approaches to frag-
ments, and James Murray, Lisa Wright, Allan Surgenor and Pawel
Dokurno have solved many hundreds of crystal structures. The PDK1
project is led by Lee Walmsley and Chris Torrance and the Hsp90
project by Martin Drysdale and Paul Brough.
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